IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.
about
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaAzaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoAutophagy inhibition by sustained overproduction of IL6 contributes to arsenic carcinogenesisThymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosisNecdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancerMolecular alterations in primary prostate cancer after androgen ablation therapy.A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun.Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq.A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsGossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway.Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.The essential role of evasion from cell death in cancer.Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesEpidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancerOncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.Dynamics of hepatic gene expression profile in a rat cecal ligation and puncture modelA major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3Preclinical studies of novel targeted therapies.R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects.STAT3 Target Genes Relevant to Human Cancers.Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.Off-target effects of plasmid-transcribed shRNAs on NFκB signaling pathway and cell survival of human melanoma cells.Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression.TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1.
P2860
Q21285161-4C6D01BB-8162-45D5-BFA9-4661808EB570Q24670297-8E1B6C75-FBA8-4F18-A131-5459A7E90D8FQ28390423-AA17C498-57A5-4E00-8596-207BE427FF5EQ28476755-5D8F5356-6C34-428A-BCE8-F3F762DD2AEEQ28477663-2CC7563F-5090-4829-8B38-B2901549CB43Q33224548-F4410EFE-619F-490F-831C-C4FD85BE30F2Q33418036-ACB07805-C737-4B89-922E-7FCACB410DAFQ33581899-97E59B00-B3F2-430D-B6EA-6390CE493A81Q33697369-D60099D8-6E83-4C9B-8708-40D4EE999321Q33797357-A2FA7068-D1F5-43B9-BBD2-6F71EAE5E2C9Q33806982-3DA011E6-56D3-457F-B62E-94A58790F449Q33889618-BCA3DD08-F736-4653-BA54-F480CE0842A1Q33909357-131E32E4-0AF5-4616-B16A-D07EA1E7F8B9Q33935165-6E702547-455F-45BD-BDD1-7578193FC87BQ34134557-64A4E314-1EF8-465C-8D5B-AF327468F9FCQ34432852-C86CA96D-0B46-44F8-A82A-7AEA333359E3Q34786411-9F5B9A52-1018-4E60-A802-0AA0FE68D93FQ35001642-363FB6D8-A383-423F-9B5E-592A500C480AQ35083049-20D08295-4C64-4B8D-9FEB-F27316340292Q35127916-A834E03B-CDBA-4685-9C3A-137811924497Q35132241-B4E5882C-619E-477B-BDDA-0C98343FADDBQ35134513-4E0E7C5D-4FBE-4AE4-A9F9-1B50BA1C54FAQ35152569-7E0D647C-0298-4E18-9C42-19877403592AQ35171777-51DDCF8E-7462-40B6-83A3-209749223991Q35551777-1737D0D1-EEEB-4EBB-9FB3-5239D41CE01CQ35579660-D1DAC224-A54B-44E3-9C89-87E57DA51FFCQ35749143-65F64E18-E3D9-439B-B9BF-4F9C887C0A1CQ36010575-EB5BECD1-CA42-48DF-829E-26EAD3E4A0EAQ36675950-C4423F43-3FD2-49B0-8C72-8A65AFF82C6EQ36711639-3FF94683-E853-4D74-9BD1-D5BDD644A24AQ36952838-299C8D00-F27E-4B47-887A-08367F09DBE2Q36998210-ACF361A1-F7A9-4367-9364-1CC66A16CDA2Q37523208-3E1A13A0-D94B-4F32-9538-6B5736BFB8E8Q38027835-3E17AC1C-0A7E-4208-A819-E8CDAC664F69Q38205362-3E392937-9BA9-4DBF-A92A-2F2AAC117A09Q38718393-3E0B5B23-C1CE-45BD-83FF-043AE966015CQ38781568-73F7CFD1-C7A9-4BFF-BFC1-E45182E4F731Q39068964-0837B24E-8BE1-420A-A863-C91F06CAA854Q39427003-25B83275-4443-49B4-AF06-95851C47C302Q39737623-907D7CA9-B43B-4FA8-AD1C-2125A2616198
P2860
IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
IL-6 up-regulates mcl-1 in hum ...... than ras / MAP kinase pathway.
@en
type
label
IL-6 up-regulates mcl-1 in hum ...... than ras / MAP kinase pathway.
@en
prefLabel
IL-6 up-regulates mcl-1 in hum ...... than ras / MAP kinase pathway.
@en
P2093
P1476
IL-6 up-regulates mcl-1 in hum ...... than ras / MAP kinase pathway.
@en
P2093
P304
P356
10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.3.CO;2-F
P407
P577
1999-12-01T00:00:00Z